Latest Hotspot

European Marketing Approval Granted to Pierre Fabre's OBGEMSA™ for Overactive Bladder Treatment

3 July 2024
3 min read

The European Commission has given approval to Pierre Fabre Laboratories to market OBGEMSA™ (vibegron) for managing symptoms of overactive bladder syndrome in adults, a condition that affects over 70 million people* throughout Europe and is notably distressing.

👇Discover comprehensive information about this drug, from its R&D status, core patents, clinical trials to approval status in global countries, by simply clicking on the image below. Dive deep into our drug database now.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

In 2022, Pierre Fabre Laboratories obtained the exclusive rights from Urovant Sciences Gmbh to register and commercialize vibegron within the European Economic Area. This decision by the European Commission (EC) will apply to all EU member countries, as well as Iceland, Liechtenstein, and Norway. The trademark OBGEMSA™ is owned by Urovant Sciences.

“We are thrilled with this progress, which will enable European patients to access a new treatment option for overactive bladder syndrome. This will further enhance our over 40 years of expertise in urology. The decision underscores Pierre Fabre Laboratories’ dedication to providing patients with innovative therapies that improve the management of chronic debilitating conditions,” stated Eric Ducournau, CEO of Pierre Fabre Laboratories.

The EC's decision is based on a favorable opinion issued by the Committee for Medicinal Products for Human Use of the European Medicines Agency on April 25. It relies on the findings from two critical, multicenter, double-blind, randomized phase 3 trials involving adults with overactive bladder symptoms. Study RVT-901-3003 assessed the 12-week efficacy, tolerability, and safety of vibegron compared to placebo and tolterodine as a positive control. Its extension, study RVT-901-3004, examined vibegron's long-term safety, tolerability, and efficacy over 52 weeks in a double-blind manner, using tolterodine as an active comparator.

In these studies, vibegron, a novel selective beta-3 adrenergic receptors (AR) agonist, showed a favorable benefit-risk profile for treating symptoms such as urgency, increased urination frequency, and urge urinary incontinence in patients with overactive bladder syndrome.

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

According to the data provided by the Synapse Database, As of Julye 3, 2024, there are 78 investigational drugs for the β3 adrenergic receptors, including 43 indications, 63 R&D institutions involved, with related clinical trials reaching 119, and as many as 4929 patents.

Vibegron represents a significant advancement in the pharmaceutical industry's efforts to address urogenital diseases, particularly in the treatment of overactive bladder syndrome and related indications. Its approval and ongoing development underscore the importance of continued research and innovation in the field of biomedicine to improve patient outcomes and quality of life.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Jul 3
Pharma Frontiers
11 min read
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Jul 3
3 July 2024
Jul 3rd latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
KBio's EV68-228-N Approved by FDA for Acute Flaccid Myelitis Treatment, Initiates Phase 1 Trial
Latest Hotspot
3 min read
KBio's EV68-228-N Approved by FDA for Acute Flaccid Myelitis Treatment, Initiates Phase 1 Trial
3 July 2024
KBio Receives FDA IND Approval for EV68-228-N to Treat Acute Flaccid Myelitis and Begins Phase 1 Trial with First Patient Dosed.
Read →
Is Fostemsavir approved by the FDA?
Drug Insights
3 min read
Is Fostemsavir approved by the FDA?
3 July 2024
The U.S. Food and Drug Administration (FDA) approved Rukobia on July 2, 2020, for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection.
Read →
FDA Approves GT Biopharma's IND Application for GTB-3650 in CD33+ Leukemia Therapy
Latest Hotspot
3 min read
FDA Approves GT Biopharma's IND Application for GTB-3650 in CD33+ Leukemia Therapy
3 July 2024
GT Biopharma Gets FDA Approval for IND Application for GTB-3650, an NK Cell Engager Targeting CD33+ Leukemia.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.